Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1/2 1

Status

Completed 39Terminated 20Withdrawn 5Unknown 2Recruiting 2Active not recruiting 2Suspended 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2Thoracic 1Plasma cell 1Other hematologic neoplasm 1Myeloid 1Head & Neck 1Gynecologic 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Neoplasms 5Multiple Myeloma 3Hematologic Neoplasms 3Thyroid Cancer, Papillary 2Neoplasms by Site 2Neoplasms by Histologic Type 2Neoplasm Metastasis 2Melanoma 2Lymphoma, Non-Hodgkin 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Thyroid Carcinoma, Anaplastic 1Rare Tumor 1Ovarian Neoplasms 1Lymphoproliferative Disorders 1Leukemia, Hairy Cell 1Laryngeal Neoplasms 1Glioma 1Erdheim-Chester Disease 1Colorectal Cancer Metastatic 1Adenocarcinoma, Follicular 1

Interventions

pembrolizumab 54Nivolumab 51Ipilimumab 29Cyclophosphamide 16binimetinib 10Specimen Handling 10Magnetic Resonance Spectroscopy 10fludarabine 9Radiosurgery 9relatlimab 8encorafenib 8Opdualag 8Interleukin-2 8Biopsy 8aldesleukin 7Blood Specimen Collection 7atezolizumab 6Immunotherapy 6cemiplimab 5CTLA-4 Antigen 5Bevacizumab 5trametinib 4dabrafenib 4Temozolomide 4Paclitaxel 4Immune Checkpoint Inhibitors 4spartalizumab 3fludarabine phosphate 3Surgical Procedures, Operative 3Metformin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Melanoma × Vemurafenib × Clear all
NCT05768178 2025-11-24

DETERMINE

Cancer Research UK

Phase 2/3 Recruiting
30 enrolled
CNSDermatologicEndocrineGastrointestinalGynecologicHead & NeckMyeloidOther hematologic neoplasmPlasma cellThoracic

Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Glioma, Laryngeal Neoplasms, Melanoma, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Ovarian Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic

NCT01638676 2021-10-29

A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients

University of Louisville

Phase 1/2 Recruiting
55 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡